Cholecystectomy: A way forward and back to metabolic syndrome?

Gabriella Garruti, David Q.H. Wang, Agostino Di Ciaula, Piero Portincasa

Research output: Contribution to journalReview articlepeer-review

20 Scopus citations


The gallbladder provides rhythmic secretion of concentrated bile acids (BAs) during fasting and postprandially contributes to digestion of dietary lipids. In addition, BAs activate metabolic pathways governing gluco-lipid homeostasis and energy expenditure via the farnesoid X nuclear receptor (FXR), G protein-coupled BA receptor 1 (GPBAR-1), and fibroblast growth factor 19 (FGF19) in the liver, intestine, brown fat, and muscle. Cholecystectomy is standard treatment worldwide for symptomatic gallstone patients. As excellently reviewed by Chen et al, cholecystectomy may disrupt enterohepatic recycling of, and signaling by, BAs. Further studies are needed to investigate whether gallbladder removal is an independent risk factor for development of the metabolic syndrome.

Original languageEnglish (US)
Pages (from-to)4-6
Number of pages3
JournalLaboratory Investigation
Issue number1
StatePublished - Jan 1 2018
Externally publishedYes

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Molecular Biology
  • Cell Biology


Dive into the research topics of 'Cholecystectomy: A way forward and back to metabolic syndrome?'. Together they form a unique fingerprint.

Cite this